nach oben

Digestive Diseases and Sciences

Erschienen in:

17.05.2018 | Review

Mucosal Ablation in Patients with Barrett’s Esophagus: Fry or Freeze?

verfasst von: Kavel Visrodia, Liam Zakko, Kenneth K. Wang

Erschienen in: Digestive Diseases and Sciences | Ausgabe 8/2018

Einloggen, um Zugang zu erhalten

Abstract

The management of Barrett’s esophagus and early esophageal adenocarcinoma has shifted away from esophagectomy and toward endoscopic techniques, including endoscopic resection and ablative therapies. The most commonly used ablative therapies are radiofrequency ablation and cryotherapy. Radiofrequency ablation has risen to the top of the management algorithm due to its favorable safety profile and established track record of efficacy in patients with dysplastic Barrett’s. Cryotherapy offers early promise as an alternatively safe and effective ablative modality. We review radiofrequency ablation and cryotherapy techniques, and updated data regarding their efficacy and safety as well as their roles in the management of Barrett’s esophagus.

Hur C, Miller M, Kong CY, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer. 2013;119:1149–1158.CrossRefPubMed

Shaheen NJ, Falk GW, Iyer PG, et al. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111:30–50. (quiz 51).CrossRefPubMed

Phoa KN, van Vilsteren FG, Weusten BL, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014;311:1209–1217.CrossRefPubMed

Medtronic. The Barrx ablation system product catalog. http://www.medtronic.com/content/dam/covidien/library/us/en/product/ablation-systems/rfa-catalog.pdf. Date accessed: January 28, 2018.

Kunzli HT, Scholvinck DW, Phoa KN, et al. Simplified protocol for focal radiofrequency ablation using the HALO90 device: short-term efficacy and safety in patients with dysplastic Barrett’s esophagus. Endoscopy. 2015;47:592–597.CrossRefPubMed

Sharma VK, Wang KK, Overholt BF, et al. Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett’s esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc. 2007;65:185–195.CrossRefPubMed

Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009;360:2277–2288.CrossRefPubMed

Duits LC, Phoa KN, Curvers WL, et al. Barrett’s oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel. Gut. 2015;64:700–706.CrossRefPubMed

Curvers WL, ten Kate FJ, Krishnadath KK, et al. Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010;105:1523–1530.CrossRefPubMed

10.

Shaheen NJ, Bulsiewicz WJ, Rothstein RI, et al. Eradication rates of Barrett’s esophagus using radiofrequency ablation (RFA): results from the U.S. RFA registry. Gastrointest Endosc. 2012;75:AB460.CrossRef

11.

Orman ES, Li N, Shaheen NJ. Efficacy and durability of radiofrequency ablation for Barrett’s Esophagus: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11:1245–1255.CrossRefPubMed

12.

Qumseya BJ, Wani S, Gendy S, et al. Disease progression in Barrett’s low-grade dysplasia with radiofrequency ablation compared with surveillance: systematic review and meta-analysis. Am J Gastroenterol. 2017;112:849–865.CrossRefPubMed

13.

van Vilsteren FG, Alvarez Herrero L, Pouw RE, et al. Predictive factors for initial treatment response after circumferential radiofrequency ablation for Barrett’s esophagus with early neoplasia: a prospective multicenter study. Endoscopy. 2013;45:516–525.CrossRefPubMed

14.

Gupta M, Iyer PG, Lutzke L, et al. Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett’s esophagus: results from a US Multicenter Consortium. Gastroenterology. 2013;145:79–86e1.CrossRefPubMedPubMedCentral

15.

Bulsiewicz WJ, Kim HP, Dellon ES, et al. Safety and efficacy of endoscopic mucosal therapy with radiofrequency ablation for patients with neoplastic Barrett’s esophagus. Clin Gastroenterol Hepatol. 2013;11:636–642.CrossRefPubMed

16.

Komanduri S, Kahrilas PJ, Krishnan K, et al. Recurrence of Barrett’s esophagus is rare following endoscopic eradication therapy coupled with effective reflux control. Am J Gastroenterol. 2017;112:556–566.CrossRefPubMed

17.

Fudman DI, Lightdale CJ, Poneros JM, et al. Positive correlation between endoscopist radiofrequency ablation volume and response rates in Barrett’s esophagus. Gastrointest Endosc. 2014;80:71–77.CrossRefPubMedPubMedCentral

18.

Pasricha S, Cotton C, Hathorn KE, et al. Effects of the learning curve on efficacy of radiofrequency ablation for Barrett’s esophagus. Gastroenterology. 2015;149:890–896e2.CrossRefPubMedPubMedCentral

19.

Qumseya BJ, Wani S, Desai M, et al. Adverse events after radiofrequency ablation in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14:1086–1095e6.CrossRefPubMed

20.

Shaheen NJ, Overholt BF, Sampliner RE, et al. Durability of radiofrequency ablation in Barrett’s esophagus with dysplasia. Gastroenterology. 2011;141:460–468.CrossRefPubMedPubMedCentral

21.

Desai M, Saligram S, Gupta N, et al. Efficacy and safety outcomes of multimodal endoscopic eradication therapy in Barrett’s esophagus-related neoplasia: a systematic review and pooled analysis. Gastrointest Endosc. 2017;85:482–495e4.CrossRefPubMed

22.

Hamade N, Sharma P. Ablation therapy for Barrett’s esophagus: new rules for changing times. Curr Gastroenterol Rep. 2017;19:48.CrossRefPubMed

23.

Das KK, Falk GW. Long-term outcomes for cryotherapy in Barrett’s esophagus with high-grade dysplasia: just cracking the ice. Gastrointest Endosc. 2017;86:633–635.CrossRefPubMed

24.

Ribeiro A, Bejarano P, Livingstone A, et al. Depth of injury caused by liquid nitrogen cryospray: study of human patients undergoing planned esophagectomy. Dig Dis Sci. 2014;59:1296–1301.CrossRefPubMed

25.

Canto MI. Cryotherapy for Barrett’s esophagus. Gastrointest Endosc Clin N Am. 2017;27:503–513.CrossRefPubMed

26.

Johnston MH, Eastone JA, Horwhat JD, et al. Cryoablation of Barrett’s esophagus: a pilot study. Gastrointest Endosc. 2005;62:842–848.CrossRefPubMed

27.

Dumot JA, Vargo JJ 2nd, Falk GW, et al. An open-label, prospective trial of cryospray ablation for Barrett’s esophagus high-grade dysplasia and early esophageal cancer in high-risk patients. Gastrointest Endosc. 2009;70:635–644.CrossRefPubMed

28.

Ghorbani S, Tsai FC, Greenwald BD, et al. Safety and efficacy of endoscopic spray cryotherapy for Barrett’s dysplasia: results of the National Cryospray Registry. Dis Esophagus. 2016;29:241–247.CrossRefPubMed

29.

Shaheen NJ, Greenwald BD, Peery AF, et al. Safety and efficacy of endoscopic spray cryotherapy for Barrett’s esophagus with high-grade dysplasia. Gastrointest Endosc. 2010;71:680–685.CrossRefPubMedPubMedCentral

30.

Sengupta N, Ketwaroo GA, Bak DM, et al. Salvage cryotherapy after failed radiofrequency ablation for Barrett’s esophagus-related dysplasia is safe and effective. Gastrointest Endosc. 2015;82:443–448.CrossRefPubMed

31.

Scholvinck DW, Kunzli HT, Kestens C, et al. Treatment of Barrett’s esophagus with a novel focal cryoablation device: a safety and feasibility study. Endoscopy. 2015;47:1106–1112.CrossRefPubMed

32.

Kunzli HT, Scholvinck DW, Meijer SL, et al. Efficacy of the CryoBalloon Focal Ablation System for the eradication of dysplastic Barrett’s esophagus islands. Endoscopy. 2017;49:169–175.PubMed

33.

National Institute of Health: US Library of Medicine. Clinicaltrials.gov. https://clinicaltrials.gov/ct2/results?cond=Barrett+Esophagus&term=cryoballoon&cntry=&state=&city=&dist. Accessed January 28, 2018.

34.

Solomon SS, Kothari S, Smallfield GB, et al. Liquid nitrogen spray cryotherapy is associated with less postprocedural pain than radiofrequency ablation in Barrett’s esophagus: a multicenter prospective study. J Clin Gastroenterol. 2018. https://doi.org/10.1097/MCG.0000000000000999 PubMedCrossRef

Titel: Mucosal Ablation in Patients with Barrett’s Esophagus: Fry or Freeze?
verfasst von: Kavel Visrodia
Liam Zakko
Kenneth K. Wang
Publikationsdatum: 17.05.2018
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 8/2018
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-018-5064-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Mucosal Ablation in Patients with Barrett’s Esophagus: Fry or Freeze?

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2018

Point–Counterpoint: Screening and Surveillance for Barrett’s Esophagus, Is It Worthwhile?

Screening and Surveillance for Barrett’s Esophagus: Is It Cost-Effective?

How Should We Report Endoscopic Results in Patient’s with Barrett’s Esophagus?

Cardiac Metaplasia: Follow, Treat, or Ignore?

Are Gastric and Esophageal Metaplasia Relatives? The Case for Barrett’s Stemming from SPEM

Histology of Barrett’s Metaplasia: Do Goblet Cells Matter?

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin